SCHEMBL3618299

SCHEMBL3618299

COc1ccccc1C(=O)N1CCCCc2cc(C(O)(C(F)(F)F)C(F)(F)F)ccc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.55
NR1H3 Q13133 5/20 0.52
KMT2A Q03164 4/20 0.48
MEN1 O00255 3/20 0.48
AVPR2 P30518 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
TP53 P04637 1/20 0.46
TSHR P16473 2/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46
ALOX15 P16050 1/20 0.46
CASP1 P29466 1/20 0.46
HTT P42858 1/20 0.46
NR1H2 P55055 2/20 0.45
PDE4A P27815 1/20 0.45
PDE4B Q07343 1/20 0.45
PDE4C Q08493 1/20 0.45
PDE4D Q08499 1/20 0.45
LMNA P02545 1/20 0.45
RORC P51449 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13317262 0.92 ALDH1A1 (0.55) ALDH1A1KMT2AMEN1AVPR2SMN1; SMN2
SCHEMBL3623469 0.84 PDE4A (0.61) ALDH1A1NR1H3KMT2AMEN1SMN1; SMN2
SCHEMBL3626970 0.83 KMT2A (0.66) ALDH1A1NR1H3KMT2AMEN1SMN1; SMN2
SCHEMBL3626841 0.82 NR1H3 (0.61) ALDH1A1NR1H3AVPR2MAPTNR1H2
SCHEMBL22340673 0.80 KMT2A (0.69) ALDH1A1KMT2AMEN1SMN1; SMN2TP53
SCHEMBL3626626 0.79 MEN1 (0.55) ALDH1A1NR1H3KMT2AMEN1SMN1; SMN2
SCHEMBL11607914 0.79 NOTUM (0.64) ALDH1A1NR1H3TP53TSHRMAPT
SCHEMBL3626417 0.79 NR1H3 (0.48) ALDH1A1NR1H3KMT2AMEN1AVPR2
SCHEMBL3626671 0.78 NR1H3 (0.53) NR1H3TP53NR1H2RORCNR1I2
SCHEMBL3618289 0.78 NR1H3 (0.51) ALDH1A1NR1H3SMN1; SMN2TP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1951676-B1 N-ACYL BENZAZEPINE DERIVATIVES AS LXR MODULATORS BRISTOL MYERS SQUIBB CO (US) 2013-07-17 EP disclosed
EP-2392567-A1 BENZOTHIAZINE DERIVATIVES AND THEIR USE AS LXR MODULATORS Bristol-Myers Squibb Company (US) 2011-12-07 EP disclosed
US-7741317-B2 LXR modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2010-06-22 US disclosed
US-7741317-B2 LXR modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2010-06-22 US disclosed
US-7741317-B2 LXR modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2010-06-22 US disclosed
EP-1951676-A2 LXR MODULATORS Brystol-Myers Squibb Company (US) 2008-08-06 EP disclosed
WO-2007050425-A2 LXR MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-05-03 WO disclosed
US-20070093470-A1 LXR modulators BRISTOL-MYERS SQUIBB COMPANY 2007-04-26 US disclosed
US-20070093470-A1 LXR modulators BRISTOL-MYERS SQUIBB COMPANY 2007-04-26 US disclosed
US-20070093470-A1 LXR modulators BRISTOL-MYERS SQUIBB COMPANY 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093470-A1 LXR modulators NR1H2, NR1H3, RXRB ALDH1A1 2274/4885NR1H3 2/4885KMT2A 492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.